| With the increasing people's living standards, China's population structure has undergone significant dietary improvements, leading to the original is called "rich man's disease" diabetes development trend of the civilian population. According to the Chinese Medical Association Diabetes credits will be published "China's diabetes and metabolic syndrome in epidemiological investigation report" shows: the incidence of diabetes in China showed rapid growth; and the domestic large and medium cities in the prevalence of adult diabetes has reached 11.66% , glucose tolerance, low population of adults accounted for 15.19%. From which to projections, China's urban diabetic patients has exceeded more than 4100 million people. Experts even predict that by 2025, China's total number of diabetic patients will reach 59.3 million people. With the increasing number of diabetic patients, diabetes medication varieties size of the market in China has also expanded year by year, the future trend of significant growth is also very evident. State Food and Drug Administration, the South Medicine Economic Research Institute data show that in 2007 the national anti-diabetes drug market has reached a size of 7.5 billion year on year increase of 20.98 percent the previous year; in 2008 off than the previous year, an increase of 13.68% , the domestic anti-diabetic drug market sales have reached 8.52 billion yuan. In accordance with national incidence of diabetes drugs of natural growth and changes in the structure predicts that by 2012, China's diabetes drug market share increased three times more than the current.Foreign investment, joint ventures, domestic major pharmaceutical markets faced with an attractive piece of cake, have increased the sales of diabetes drug efforts, both in traditional hospital market, or the pharmacy community in the emerging retail market, the company's the competition between have become a fierce one.H Pharmaceuticals, Inc. is the emerging private small and medium pharmaceutical companies, pharmaceutical companies in China in 4768, the top 900. H pharmaceutical companies, although the few local companies that have a series of oral diabetes variety of manufacturers, but, after all, limited by its own power, whether in the corporate brand, sales volume, or financial strength, marketing strength, and internal systems can not be Drug makers are compared, not to mention even in many multinational pharmaceutical predators, Germany, Bayer, GlaxoSmithKline, Novo Nordisk and so on are fully engaged, close combat diabetes market to compete, survive, seek was the development, introduction and implementation of effective marketing strategy which became the H the greatest challenge facing the pharmaceutical companies.Based on the I practical work of H pharmaceutical companies in the pharmaceutical industry, understanding integrated application of theoretical knowledge learned in marketing to H types of diabetes pharmaceutical companies operating reality as background, analysis of pharmaceutical companies outside H the competitive environment; summarized the diabetes market, industry characteristics and trends, summarizes the evolution of diabetes, the pattern of market competition and competitive manufacturers market practices, analyzed the course of diabetic patients at different stages of consumers in behavior characteristics; combing the H pharmaceutical companies Marketing situation and marketing problems; conduct SWOT analysis of the basis, through market segmentation is proposed for the species H diabetes pharmacy pharmaceutical companies marketing strategy; based pharmaceutical company H to determine the product strategies, pricing strategies, channel strategy, marketing strategy, restructuring of the marketing team, implementing a marketing strategy targeted pharmacies, opening up a powerful competitors not pay enough attention to new markets, expanding sales, has won the trust of patients with diabetes. H pharmaceutical companies also seek to life, finding a development, access to respected. |
PDF Full Text Request